Many of you have been following and evaluating your options as multiple manufacturers have restricted contract pharmacy pricing for CEs. You probably also received our email communication in February describing a few exception opportunities that exist for AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi, if you do not have an inhouse pharmacy. If you did
Read MoreA topic we have covered in our client newsletter in the past, but is long overdue for a full discussion is 340B actual acquisition cost (AAC) requirements for fee-for-service (FFS) Medicaid billing in many states. In 340B audits we perform for clients, we review the AAC requirement and note if there is any risk. However,
Read MoreHistorically, HRSA auditors have requested a list of eligible providers from covered entities during HRSA audits. Recently, however, HRSA auditors have been requesting that covered entities upload documents demonstrating that, for each audited utilization record, the prescriber was (at the time the medication was administered or prescription written) employed by, under contract with, or had
Read MoreThe end of 2020 is upon us, for better or worse, and the healthcare industry as a whole is envisioning a brighter 2021 ahead of us, especially with the availability of two new COVID-19 vaccines that could signal an end to the pandemic. But we want to make sure our hospital 340B covered entities are
Read MoreThe 340B Program is complicated. It’s intimidating, and let’s be honest, at times downright confusing, for newcomers and veterans alike. Those of us in the 340B world know that managing a successful 340B Program requires the juggling of what feels like a million things at once. Between keeping up with state Medicaid requirements, HRSA audit preparation, multiple third-party administrators, NDC crosswalks
Read MoreIn 2010, the Affordable Care Act (ACA) was signed into law, changing the approach to healthcare in the United States. These changes had far reaching impacts but for today, we’re going to focus on the implications the ACA had on 340B and what the potential changes to the ACA could mean for the future of
Read MoreThe Turnkey team of Rich and Rich clearly have extensive hospital experience with 340B and were able to quickly understand our operational issues and provide clear recommendations. When our team had questions months later they promptly responded to each request with thoughtful and specific advice.
We have contracted Turnkey Rx Solutions for almost a year now. We're very impressed with the work they have been able to provide us. They understand the high standards that our health system has and have been the efficient delivering. I highly recommend working with them.
Turnkey Solutions was well prepared for our mock audit and knew just what questions to ask and where to look for improvement opportunities. They easily found the needles in the haystack and took the time to understand our practice to make the best suggestions for improvement. ... It was a delight to work with them and I will contract with them again in the future.
We have been extremely satisfied with the assistance Turnkey Pharmacy Solutions has provided to us as our 340B program has expanded. We have worked with Rich and Rob and find them to be extremely knowledgeable, thorough, and personable. Their mission was to identify and minimize any potential risk areas within our 340B program. As a result, we feel very confident in our processes.
TurnKey is very knowledgeable of the 340B Program. They identified potential risk areas for our organization and provided us with the necessary corrective action. Thanks to TurnKey, we identified and addressed those risk areas and are now better prepared for a HRSA Audit.
The information and resources that were provided through the audit process with Turnkey have been invaluable. We will definitely continue to work with them in the future to ensure our program compliance.
Together, we can get your 340B Program HRSA compliant!